Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for iberdomide combined with standard treatment (daratumumab ...

Caring for someone with multiple myeloma can be challenging on many levels. The person who has just been diagnosed may look to you for information to help them better understand the disease to ...

Biologic heterogeneity in myeloma supports subtype-specific approaches, and t(4;14) defines a clinically meaningful subset with distinct pathway activation and historically aggressive behavior.

TEACHEY - Six of seven schools in the newly-aligned Swine Valley 2A-3A Conference emerged as a conference champion in at least one sport during fall competition. Wallace-Rose Hill claimed co-ownership ...

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple myeloma treatment paradigm, the drug is still finding ways to consolidate its ...

ISP Sgt. John Perrine said the closure was being made around 11:15 a.m. Jan. 27. An INDOT alert around an hour later said all lanes had reopened. Roads around central Indiana continue to be a ...

Daratumumab and hyaluronidase-fihj is now FDA-approved for newly diagnosed multiple myeloma patients ineligible for ASCT, in combination with VRd. The phase 3 CEPHEUS trial showed significant ...

Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II) For over half a ...

D-VRd is the first anti-CD38 antibody-based regimen approved for all newly diagnosed multiple myeloma patients, regardless of transplant eligibility. The CEPHEUS trial demonstrated significant ...